|EthicAd is a nonprofit, independent organization committed to providing the most accurate and relevant information about prescription medications. We do not accept funding from the pharmaceutical industry. Being nonprofit and independent allows us to be unbiased in helping direct-to-consumer (DTC) advertising to evolve in a socially responsible way – a way that benefits the consumer the most. |
Executive Committee members with ties to industry include:
Donna Hill Howes, RN, MS. Chairman of the board. Director of Health Education, Time Inc. Health
Marc Scheineson, JD, General Council. Partner at Alston + Bird and former Associate Commissioner for Legislative Affairs of the Food and Drug Administration. Alston + Bird, a Washington, D.C.-based lobbying firm, represents numerous pharmaceutical and health-related companies. (http://www.alston.com/marc_scheineson/; accessed 9/08/08)
Michael Shaw, MD., Executive Director, President, Shaw Science Partners, Inc., which generated $1.6 million dollars in annual sales in 2006 from pharmaceutical messaging consulting.
Steering Committee members with ties to industry include:
Laura Benson, director of medical communications at OSI Pharmaceuticals in Melville, NY.
Henry R. Black, MD., Clinical Professor of Internal Medicine, Director of Hypertension Research, New York University School of Medicine, New York. Received honoraria for serving as a speaker for Bristol-Myers Squibb, Novartis, Pfizer, Pharmacia, and Wyeth-Ayerst; received grants from Bristol-Myers Squibb, Merck, Pfizer, Pharmacia, and Boehringer Ingelheim; served as a consultant to Merck, Abbott, AstraZeneca, Biovail, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Pharmacia. (JAMA. 2003;289:2560-72.)
John H. Greist, MD., Director, Healthcare Technology Systems, Inc., Senior Scientist, Madison Institute of Medicine, Inc. Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin. HTS provides services to the pharmaceutical. (http://www.healthtechsys.com/products/prodrsch.html; accessed 9/10/08)
Michael A. Jenike, MD., Professor of Psychiatry, Harvard Medical School, Boston. Research funding received from Eli Lilly, Ciba-Geigy, Solvay, Pfizer, GlaxoSmithKline, Warner Lambert, Kali-Duphar, and Sandoz. Currently working on obsessive-compulsive disorder research with $10 million grant from a Houston based furniture store owner in coordination with Massachusetts General Hospital. (http://www.mclean.harvard.edu/pdf/about/bios/cv-mjenike.pdf; accessed 9/10/08)
Sheldon H. Preskorn, MD., Professor and Vice-Chairman Department of Psychiatry University of Kansas School of Medicine, Wichita. Principal investigator, speaker or consultant for AstraZeneca, Aventis, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Eisai, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Johnson & Johnson, Lundbeck, Merck, Neurosearch, Novartis, Organon, Otusak, Pfizer, Solvay, Sommerset, Sumitomo, Wyeth, and Yamanouchi. (http://www.ajmc.com/Article.cfm?ID=2645; accessed 9/10/08).
Michael Weber, M.D., Professor of Medicine, The State University of New York Downstate Medical Center, Brooklyn. Received funding from Novartis for his study on cardiovascular risk in hypertensive patients. (Lancet. 2004;363:2022.) Consulted for Pfizer, Merck and Bristol-Myers Squibb. (http://www.medscape.com/viewarticle/481819; accessed 6/28/06)